• allan said: hi .. svilena hristova i had cheated by a chinese company in senzhen. i...
• Svilena Hristova said: Hi, i live in China and i will try to help you. Send me email...
• Jhummun S said: I made payment a huge sum for an order on 13/12/2011 by credit card...
• steve said: can i use roaming service in Yangon, Myanmar using this china sin card ?
• norm said: I would like to know that also. Feb. 2006 I aquired shares.
• baove said: Is it just me or does it seem that Vietnamese are strong supporters of...
• Clifford Mensch said: I would like to offer property for sale to investors, 60 acres...
• Clem said: 100,000 employees, 200,000 iphones produced daily. I wonder what kind of...
• Trizt said: I really hope they do pay the workes for all the extra hours they will...
Get Our Weekly Email Newsletter
2012 International Conference on Green Building and Civil Engineering @ Guizhou - 2012/05/19
Annual Conference of the Academy of Innovation and Entrepreneurship 2012 @ Macau - 2012/06/08
SARS Antibody Sent For Preclinical Testing
April 27, 2004 |
Print
| 
Email
| 
Comments | Category: Science
Responding to a request from a Chinese biotechnology company working closely with officials in China, Medarex, Inc. and the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) have shipped to Beijing a sample of the fully human antibody to SARS developed by Medarex and MBL/UMMS.
The antibody was sent to Sinovac Biotech Co., Ltd. for preclinical testing against SARS strains used for their vaccine and the control strain from previous cases in China.
In response to the recent outbreak of SARS, and to assist with research on potential therapies, Beijing-based Sinovac submitted this idea to the Chinese State Food and Drug Administration and received support to test the Medarex/MBL/UMMS antibody before any further action. Sinovac plans to conduct preclinical tests to determine the antibody's effectiveness in neutralizing the strains of the SARS virus.
As previously announced, MBL/UMMS partnered with Medarex to use Medarex's UltiMAb technology to generate fully human antibodies with the potential to treat SARS. Under the terms of the agreement, Medarex and MBL expect to share equally the full development costs of any antibody products as well as any future revenues arising from these products.
Related Links:
Recommend this page: 
Loading ...Leave A Comment:
-
Security
- Qihoo 360's Safebox Software Will Integrate With Uuu9.com
- Apple Suspends iPhone 4S Sales In Retail Stores In China
- New Chinese Internet Rules Focus On Data Security, Web Advertising
- Chinese Internet Users Can Report Online Fraudsters Via New Baidu Service
- Huawei To Acquire 49% Stake In Security JV With Symantec
-
Software
-
Telecom & Wireless
Copyright 2012 ChinaTechNews.com. All Rights Reserved.
If you would like to syndicate these articles and posts for personal non-business use where you will not gain in any monetary way, please utilize the RSS feed for this online publication, which provides a brief summary of each post with a link back to the original article. Posting of any other part of the articles or posts on this website, in whole or in part, is expressly prohibited without express written permission from ChinaTechNews.com. No part of this website may be copied, transferred, posted, or published without the express written permission of ChinaTechNews.com or its registered agents. Content on this website, including articles, opinions, and data are protected under international copyright laws. Failure to comply with these rules will result in legal action. 